Biolife Sciences Stock Performance
| BLFE Stock | USD 0.0001 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and BioLife Sciences are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days BioLife Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's technical and fundamental indicators remain rather sound which may send shares a bit higher in August 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
BioLife |
BioLife Sciences Relative Risk vs. Return Landscape
If you would invest 0.01 in BioLife Sciences on April 27, 2025 and sell it today you would lose (0.01) from holding BioLife Sciences or give up 100.0% of portfolio value over 90 days. BioLife Sciences is currently does not generate positive expected returns and assumes 12.7% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than BioLife, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioLife Sciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioLife Sciences' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as BioLife Sciences, and traders can use it to determine the average amount a BioLife Sciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.127
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BLFE |
Estimated Market Risk
| 12.7 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.61 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BioLife Sciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioLife Sciences by adding BioLife Sciences to a well-diversified portfolio.
BioLife Sciences Fundamentals Growth
BioLife Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of BioLife Sciences, and BioLife Sciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioLife Pink Sheet performance.
| Current Valuation | 1.01 M | |||
| Price To Sales | 0 X | |||
| Cash And Equivalents | 15.62 K | |||
| Total Debt | 398 K | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (106.55 K) | |||
| Earnings Per Share | (0.01) X | |||
About BioLife Sciences Performance
By analyzing BioLife Sciences' fundamental ratios, stakeholders can gain valuable insights into BioLife Sciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioLife Sciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioLife Sciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Bio Life Sciences Corp. develops, licenses, and distributes antibacterial products and non-contact human temperature screening technology. Bio Life Sciences Corp. was incorporated in 2018 and is based in Mississauga, Canada. Biolife Sciences operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 3 people.Things to note about BioLife Sciences performance evaluation
Checking the ongoing alerts about BioLife Sciences for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for BioLife Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioLife Sciences generated a negative expected return over the last 90 days | |
| BioLife Sciences has high historical volatility and very poor performance | |
| BioLife Sciences has some characteristics of a very speculative penny stock | |
| BioLife Sciences has high likelihood to experience some financial distress in the next 2 years | |
| BioLife Sciences currently holds 398 K in liabilities. BioLife Sciences has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist BioLife Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, BioLife Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioLife Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioLife to invest in growth at high rates of return. When we think about BioLife Sciences' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (456.87 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| BioLife Sciences currently holds about 15.62 K in cash with (106.55 K) of positive cash flow from operations. |
- Analyzing BioLife Sciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioLife Sciences' stock is overvalued or undervalued compared to its peers.
- Examining BioLife Sciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioLife Sciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioLife Sciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioLife Sciences' pink sheet. These opinions can provide insight into BioLife Sciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioLife Pink Sheet analysis
When running BioLife Sciences' price analysis, check to measure BioLife Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Sciences is operating at the current time. Most of BioLife Sciences' value examination focuses on studying past and present price action to predict the probability of BioLife Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Sciences' price. Additionally, you may evaluate how the addition of BioLife Sciences to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |